Boston Ebit vs Research Development Analysis

0HOY Stock

89.13 0.07 0.08%

Boston Scientific financial indicator trend analysis is way more than just evaluating Boston Scientific Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Boston Scientific Corp is a good investment. Please check the relationship between Boston Scientific Ebit and its Research Development accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Boston Scientific Corp Ebit account and Research Development. At this time, the significance of the direction appears to have strong relationship.

The correlation between Boston Scientific's Ebit and Research Development is 0.76. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Research Development in the same time period over historical financial statements of Boston Scientific Corp, assuming nothing else is changed. The correlation between historical values of Boston Scientific's Ebit and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Boston Scientific Corp are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Ebit i.e., Boston Scientific's Ebit and Research Development go up and down completely randomly.

Correlation Coefficient

0.76

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Ebit

Research Development

Most indicators from Boston Scientific's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Boston Scientific Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Tax Provision is likely to gain to about 43.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.1 B in 2024.

	2021	2022	2023	2024 (projected)
Total Revenue	11.9B	12.7B	14.2B	10.6B
Depreciation And Amortization	1.1B	1.1B	1.2B	1.0B

Total Revenue Depreciation And Amortization

Boston Scientific fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Short Long Term Debt Total	Short Term Investments
Total Assets		0.55	0.59	0.99	0.98	0.82	0.94	0.9	0.71	1.0	0.51	0.95	0.71	0.9	0.97	0.63	0.83	0.92	0.57	0.91	0.96	0.95	0.31	0.78	0.96	0.67
Other Current Liab	0.55		0.9	0.49	0.54	0.75	0.5	0.67	0.57	0.55	0.75	0.49	0.57	0.68	0.56	0.34	0.58	0.56	0.06	0.49	0.65	0.59	0.05	0.64	0.63	0.88
Total Current Liabilities	0.59	0.9		0.52	0.56	0.75	0.53	0.67	0.55	0.59	0.67	0.49	0.55	0.75	0.6	0.39	0.51	0.59	-0.06	0.47	0.68	0.57	0.23	0.55	0.68	0.81
Total Stockholder Equity	0.99	0.49	0.52		0.99	0.76	0.93	0.91	0.69	0.99	0.46	0.93	0.69	0.88	0.98	0.63	0.78	0.93	0.59	0.93	0.91	0.95	0.22	0.79	0.92	0.6
Property Plant And Equipment Net	0.98	0.54	0.56	0.99		0.76	0.94	0.93	0.65	0.98	0.49	0.92	0.65	0.91	0.99	0.65	0.76	0.96	0.53	0.94	0.9	0.94	0.2	0.84	0.9	0.62
Net Debt	0.82	0.75	0.75	0.76	0.76		0.74	0.74	0.6	0.82	0.85	0.76	0.6	0.84	0.78	0.32	0.94	0.76	0.33	0.65	0.88	0.77	0.32	0.72	0.89	0.83
Retained Earnings	0.94	0.5	0.53	0.93	0.94	0.74		0.85	0.63	0.94	0.52	0.99	0.63	0.87	0.92	0.8	0.77	0.88	0.52	0.95	0.9	0.89	0.35	0.82	0.9	0.64
Accounts Payable	0.9	0.67	0.67	0.91	0.93	0.74	0.85		0.66	0.9	0.55	0.81	0.65	0.92	0.95	0.6	0.69	0.92	0.32	0.88	0.82	0.86	0.05	0.81	0.82	0.68
Cash	0.71	0.57	0.55	0.69	0.65	0.6	0.63	0.66		0.67	0.46	0.65	1.0	0.49	0.65	0.39	0.65	0.49	0.66	0.71	0.71	0.85	-0.06	0.52	0.71	0.57
Non Current Assets Total	1.0	0.55	0.59	0.99	0.98	0.82	0.94	0.9	0.67		0.51	0.94	0.67	0.92	0.97	0.63	0.83	0.93	0.53	0.89	0.96	0.93	0.35	0.76	0.97	0.67
Non Currrent Assets Other	0.51	0.75	0.67	0.46	0.49	0.85	0.52	0.55	0.46	0.51		0.52	0.46	0.61	0.53	0.17	0.78	0.54	0.15	0.47	0.58	0.55	0.01	0.73	0.58	0.74
Other Assets	0.95	0.49	0.49	0.93	0.92	0.76	0.99	0.81	0.65	0.94	0.52		0.65	0.83	0.9	0.75	0.82	0.85	0.59	0.92	0.93	0.9	0.4	0.78	0.91	0.63
Cash And Short Term Investments	0.71	0.57	0.55	0.69	0.65	0.6	0.63	0.65	1.0	0.67	0.46	0.65		0.49	0.65	0.39	0.65	0.49	0.66	0.71	0.71	0.85	-0.06	0.52	0.71	0.57
Net Receivables	0.9	0.68	0.75	0.88	0.91	0.84	0.87	0.92	0.49	0.92	0.61	0.83	0.49		0.94	0.64	0.72	0.94	0.19	0.81	0.87	0.79	0.33	0.81	0.88	0.75
Good Will	0.97	0.56	0.6	0.98	0.99	0.78	0.92	0.95	0.65	0.97	0.53	0.9	0.65	0.94		0.64	0.76	0.97	0.46	0.93	0.89	0.92	0.19	0.83	0.91	0.67
Common Stock Shares Outstanding	0.63	0.34	0.39	0.63	0.65	0.32	0.8	0.6	0.39	0.63	0.17	0.75	0.39	0.64	0.64		0.29	0.6	0.26	0.78	0.59	0.57	0.34	0.59	0.58	0.49
Non Current Liabilities Total	0.83	0.58	0.51	0.78	0.76	0.94	0.77	0.69	0.65	0.83	0.78	0.82	0.65	0.72	0.76	0.29		0.71	0.56	0.69	0.87	0.81	0.29	0.7	0.87	0.71
Inventory	0.92	0.56	0.59	0.93	0.96	0.76	0.88	0.92	0.49	0.93	0.54	0.85	0.49	0.94	0.97	0.6	0.71		0.35	0.87	0.83	0.85	0.18	0.88	0.84	0.63
Other Current Assets	0.57	0.06	-0.06	0.59	0.53	0.33	0.52	0.32	0.66	0.53	0.15	0.59	0.66	0.19	0.46	0.26	0.56	0.35		0.61	0.5	0.71	-0.06	0.38	0.52	0.19
Other Stockholder Equity	0.91	0.49	0.47	0.93	0.94	0.65	0.95	0.88	0.71	0.89	0.47	0.92	0.71	0.81	0.93	0.78	0.69	0.87	0.61		0.81	0.92	0.06	0.85	0.82	0.62
Total Liab	0.96	0.65	0.68	0.91	0.9	0.88	0.9	0.82	0.71	0.96	0.58	0.93	0.71	0.87	0.89	0.59	0.87	0.83	0.5	0.81		0.9	0.48	0.7	0.99	0.77
Total Current Assets	0.95	0.59	0.57	0.95	0.94	0.77	0.89	0.86	0.85	0.93	0.55	0.9	0.85	0.79	0.92	0.57	0.81	0.85	0.71	0.92	0.9		0.1	0.8	0.91	0.66
Intangible Assets	0.31	0.05	0.23	0.22	0.2	0.32	0.35	0.05	-0.06	0.35	0.01	0.4	-0.06	0.33	0.19	0.34	0.29	0.18	-0.06	0.06	0.48	0.1		-0.04	0.45	0.23
Common Stock	0.78	0.64	0.55	0.79	0.84	0.72	0.82	0.81	0.52	0.76	0.73	0.78	0.52	0.81	0.83	0.59	0.7	0.88	0.38	0.85	0.7	0.8	-0.04		0.7	0.66
Short Long Term Debt Total	0.96	0.63	0.68	0.92	0.9	0.89	0.9	0.82	0.71	0.97	0.58	0.91	0.71	0.88	0.91	0.58	0.87	0.84	0.52	0.82	0.99	0.91	0.45	0.7		0.78
Short Term Investments	0.67	0.88	0.81	0.6	0.62	0.83	0.64	0.68	0.57	0.67	0.74	0.63	0.57	0.75	0.67	0.49	0.71	0.63	0.19	0.62	0.77	0.66	0.23	0.66	0.78

Click cells to compare fundamentals

Boston Scientific Account Relationship Matchups

Boston Scientific fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	30.6B	30.8B	32.2B	32.5B	35.1B	26.4B
Other Current Liab	2.7B	2.8B	2.7B	2.4B	3.2B	2.8B
Total Current Liabilities	4.9B	3.7B	4.3B	3.8B	4.9B	4.1B
Total Stockholder Equity	13.9B	15.3B	16.6B	17.6B	19.3B	12.0B
Property Plant And Equipment Net	2.4B	2.5B	2.7B	2.8B	3.3B	2.3B
Net Debt	9.8B	7.7B	7.4B	8.2B	8.7B	6.5B
Retained Earnings	(2.3B)	(2.4B)	(1.4B)	(750M)	819M	860.0M
Accounts Payable	542M	513M	794M	862M	942M	543.4M
Cash	563M	1.9B	2.1B	1.1B	865M	927.8M
Non Current Assets Total	25.9B	24.1B	25.9B	26.7B	28.6B	21.4B
Non Currrent Assets Other	144M	166M	225M	442M	4.5B	4.7B
Other Assets	4.6B	4.5B	4.6B	4.6B	5.3B	5.5B
Cash And Short Term Investments	563M	1.9B	2.1B	1.1B	865M	928.1M
Net Receivables	1.9B	1.5B	1.8B	2.0B	2.2B	1.7B
Good Will	10.2B	10.0B	12.0B	12.9B	14.4B	9.6B
Common Stock Shares Outstanding	1.4B	1.4B	1.4B	1.4B	1.5B	1.5B
Non Current Liabilities Total	11.8B	11.8B	11.3B	11.1B	10.7B	9.8B
Inventory	1.6B	1.4B	1.6B	1.9B	2.5B	1.5B
Other Current Assets	624M	2.3B	1.2B	1.3B	937M	949.8M
Other Stockholder Equity	15.8B	17.5B	17.7B	18.0B	18.4B	17.8B
Total Liab	16.7B	15.5B	15.6B	14.9B	15.6B	14.4B
Total Current Assets	4.7B	6.7B	6.3B	5.8B	6.5B	5.0B
Intangible Assets	8.2B	6.1B	6.2B	6.0B	6.0B	6.8B
Short Long Term Debt Total	10.4B	9.6B	9.5B	9.3B	9.6B	8.1B
Liabilities And Stockholders Equity	30.6B	30.8B	32.2B	32.5B	35.1B	27.1B
Accumulated Other Comprehensive Income	270M	207M	263M	268M	50M	47.5M
Short Term Debt	1.5B	83M	332M	81M	607M	711.3M
Long Term Debt	3.8B	4.8B	8.6B	9.1B	10.5B	7.0B
Capital Surpluse	17.2B	17.3B	17.6B	19.7B	22.7B	19.5B
Property Plant Equipment	2.4B	2.5B	2.7B	2.8B	3.3B	2.4B
Other Liab	3.0B	2.2B	2.1B	1.8B	1.6B	1.9B
Net Tangible Assets	(4.5B)	(760M)	(1.6B)	(1.3B)	(1.5B)	(1.6B)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Boston Stock Analysis

When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Boston Ebit vs Research Development Analysis

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

Correlation Coefficient

Ebit

Research Development

Boston Scientific fundamental ratios Correlations

Boston Scientific Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Boston Scientific fundamental ratios Accounts

Also Currently Popular

Additional Tools for Boston Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Total Stockholder Equity
Non Current Assets Total	+ 0.99	Total Stockholder Equity
Good Will	+ 0.99	Property Plant And Equipment Net

Intangible Assets	- 0.06	Other Current Assets
Intangible Assets	- 0.06	Cash And Short Term Investments
Intangible Assets	- 0.06	Cash
Other Current Assets	- 0.06	Total Current Liabilities
Common Stock	- 0.04	Intangible Assets